Phaseline

Companies › MBrace Therapeutics

MBrace Therapeutics: clinical trials, targets and expected readouts

2 active drug programs in 2 registered trials: 2 Phase 1; Oncology; next expected readout Nov 2026.

Open in Phaseline: competitors, likelihood bands and readouts Company report

Programs

DrugTargetHighest phaseConditionsNext expected readout
MBRC-101
anti-EPHA5 antibody-drug conjugate with monomethyl auristatin E (MMAE) payload
EPHA5Phase 1CancerNov 2026
MBRC-201 ADC
antibody-drug conjugate
–Phase 1Prostate Cancer Castration-resistant Prostate CancerSep 2029

Trials

Registry idDrugPhaseConditionsAreaExpected readout
NCT06014658MBRC-101Phase 1CancerOncologyNov 2026
NCT07145255MBRC-201 ADCPhase 1Prostate Cancer Castration-resistant Prostate CancerOncologySep 2029

Targets

EPHA5 (1)

Companies with the same targets

–

Programs group the company's trials by drug; the target and mechanism come from Open Targets and ChEMBL via Open Targets; expected readouts are Phaseline's estimate from the registry's primary completion date. Facts from the registries only; the approval likelihood, shown as a band with its track record, is in the app.